Cadre (CDRE) Competitors $30.99 +1.36 (+4.58%) Closing price 03:59 PM EasternExtended Trading$31.06 +0.07 (+0.24%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDRE vs. GKOS, BLCO, SLNO, TMDX, NVST, LIVN, WRBY, INSP, PRCT, and LMATShould you be buying Cadre stock or one of its competitors? The main competitors of Cadre include Glaukos (GKOS), Bausch + Lomb (BLCO), Soleno Therapeutics (SLNO), TransMedics Group (TMDX), Envista (NVST), LivaNova (LIVN), Warby Parker (WRBY), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry. Cadre vs. Its Competitors Glaukos Bausch + Lomb Soleno Therapeutics TransMedics Group Envista LivaNova Warby Parker Inspire Medical Systems PROCEPT BioRobotics LeMaitre Vascular Cadre (NYSE:CDRE) and Glaukos (NYSE:GKOS) are both medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Do analysts recommend CDRE or GKOS? Cadre currently has a consensus target price of $31.50, indicating a potential upside of 1.66%. Glaukos has a consensus target price of $127.42, indicating a potential upside of 35.25%. Given Glaukos' stronger consensus rating and higher probable upside, analysts plainly believe Glaukos is more favorable than Cadre.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadre 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Glaukos 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.79 Which has more volatility and risk, CDRE or GKOS? Cadre has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Is CDRE or GKOS more profitable? Cadre has a net margin of 6.65% compared to Glaukos' net margin of -21.43%. Cadre's return on equity of 12.08% beat Glaukos' return on equity.Company Net Margins Return on Equity Return on Assets Cadre6.65% 12.08% 5.60% Glaukos -21.43%-8.59%-6.61% Which has higher valuation and earnings, CDRE or GKOS? Cadre has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCadre$567.56M2.22$36.13M$0.9432.96Glaukos$383.48M14.09-$146.37M-$1.65-57.10 Does the media prefer CDRE or GKOS? In the previous week, Glaukos had 10 more articles in the media than Cadre. MarketBeat recorded 12 mentions for Glaukos and 2 mentions for Cadre. Cadre's average media sentiment score of 1.53 beat Glaukos' score of 1.50 indicating that Cadre is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadre 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Glaukos 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders and institutionals hold more shares of CDRE or GKOS? 44.0% of Cadre shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 31.5% of Cadre shares are held by company insiders. Comparatively, 5.8% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryCadre beats Glaukos on 10 of the 17 factors compared between the two stocks. Get Cadre News Delivered to You Automatically Sign up to receive the latest news and ratings for CDRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDRE vs. The Competition Export to ExcelMetricCadrePROTECTION IndustryIndustrials SectorNYSE ExchangeMarket Cap$1.20B$2.16B$7.65B$20.94BDividend Yield1.28%1.87%4.56%3.58%P/E Ratio32.9619.0625.7926.59Price / Sales2.224.0399.7055.16Price / Cash20.9269.9828.3923.54Price / Book3.794.084.095.45Net Income$36.13M$110.39M$796.69M$992.10M7 Day Performance6.67%1.46%0.60%2.62%1 Month Performance-5.51%-1.97%1.19%2.51%1 Year Performance-11.47%24.86%27.76%12.94% Cadre Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDRECadre2.0185 of 5 stars$30.99+4.6%$31.50+1.7%-16.7%$1.20B$567.56M32.962,284GKOSGlaukos4.7647 of 5 stars$86.94+2.7%$127.42+46.6%-30.9%$4.85B$383.48M-52.69780Positive NewsBLCOBausch + Lomb2.2558 of 5 stars$13.66+0.1%$15.56+13.9%-10.1%$4.83B$4.79B-17.5113,500SLNOSoleno Therapeutics4.5809 of 5 stars$85.76+4.1%$113.30+32.1%+34.6%$4.38BN/A-20.7130News CoverageAnalyst ForecastAnalyst RevisionTMDXTransMedics Group2.8881 of 5 stars$127.26+11.1%$123.00-3.3%-31.3%$3.90B$441.54M65.94210Positive NewsNVSTEnvista3.8535 of 5 stars$20.19-0.3%$20.92+3.7%+13.5%$3.36B$2.51B63.0812,300LIVNLivaNova1.7935 of 5 stars$49.56+1.5%$59.29+19.6%+14.2%$2.67B$1.25B-12.742,900Positive NewsAnalyst ForecastWRBYWarby Parker2.2898 of 5 stars$23.25-0.4%$24.06+3.5%+85.6%$2.44B$771.32M-332.023,780Positive NewsINSPInspire Medical Systems4.9348 of 5 stars$79.62+0.6%$173.31+117.7%-51.0%$2.34B$802.80M46.021,246Positive NewsShort Interest ↓PRCTPROCEPT BioRobotics3.608 of 5 stars$38.77+0.9%$74.88+93.1%-52.8%$2.14B$224.50M-25.01430LMATLeMaitre Vascular2.2643 of 5 stars$92.62+0.4%$98.00+5.8%+11.5%$2.09B$219.86M44.96490Positive News Related Companies and Tools Related Companies GKOS Alternatives BLCO Alternatives SLNO Alternatives TMDX Alternatives NVST Alternatives LIVN Alternatives WRBY Alternatives INSP Alternatives PRCT Alternatives LMAT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CDRE) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadre Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadre With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.